The Time Has Come: Surgical Administration of Durable Medical Therapy...

720 S Michigan Ave,Chicago IL 60605

30 September, 2022

Description

Activity ChairArshad M. Khanani, MD, MA, FASRS Managing Partner Director of Clinical Research Director of Fellowship Sierra Eye Associates Clinical Associate Professor University of Nevada Reno, NV FacultySara J. Haug, MD, PhD Partner, Southwest Eye Consultants, Durango, CO Director of Clinical Research Southwest Retina Research Center Durango, CO Dante J. Pieramici, MD Director, California Retina Research Foundation Partner, California Retina Consultants Santa Barbara, CA Lejla Vajzovic, MD, FASRS Director, Duke Surgical Vitreoretinal Fellowship Program Director, Duke Center for Artificial and Regenerative Vision Co-Director, Duke Pediatric Retina and Optic Nerve Center Director, Duke Eye Center Continuing Medical Education Director, Duke fAVS and AVS Courses Associate Professor of Ophthalmology Adult and Pediatric Vitreoretinal Surgery and Diseases Duke University Eye Center Durham, NC OverviewSuboptimal outcomes in patients with retinal vascular diseases receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy have been associated with loss of adherence due to treatment burden. However, novel delivery devices and gene therapies that reduce the need for frequent dosing have now been developed. The Port Delivery System (PDS) with ranibizumab was recently FDA-approved for the management of patients with neovascular age-related macular degeneration (nAMD), while gene therapies are currently being evaluated in ongoing clinical studies. To achieve optimal efficacy and safety outcomes, these novel delivery modalities require unique surgical approaches for their implication into clinical practice. In this CME activity, experts in the field will discuss the risks and benefits of intravitreal versus surgical administration of agents used in the management of patients with retinal vascular diseases, evaluate new and emerging surgically delivered therapies that can enhance outcomes by reducing treatment burden, and provide best practices that can reduce the potential for complications when utilizing the PDS with ranibizumab or subretinal gene therapy in the management of patients with nAMD. Agenda6:00 PM Registration and Dinner 6:30 PM Introduction and Pretest Arshad M. Khanani, MD, MA 6:35 PM Extending Treatment Intervals in Retinal Vascular Diseases: Are We There Yet? Sara J. Haug, MD, PhD 6:50 PM Deep Dive Into the PDS Dante J. Pieramici, MD 7:15 PM RGX314: Assessing New Evidence Lejla Vajzovic, MD 7:30 PM Case Presentations Arshad M. Khanani, MD, MA 7:45 PM Posttest and Question & Answer 8:00 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Compare the risks and benefits of intravitreal versus surgical administration of agents used in the management of retinal vascular diseases. Apply current evidence to practice regarding new and emerging surgically delivered therapies that can enhance outcomes in patients with retinal vascular diseases by reducing treatment burden. Incorporate best practices that can reduce the potential for complications when using the PDS or subretinal gene therapy for nAMD. Target AudienceThe intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with retinal vascular diseases. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This activity is not affiliated with the official program of AAO 2022. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.